nejm tirzepatide SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants VisualAbstract: Tirzepatide Improved Outcomes in
Description
On September 16, 2025 , the FDA issued warning letters to more than 50 compounding pharmacies and telehealth companies , including Hims & Hers , for selling unapproved GLP-1s and making misleading claims
Efruxifermin phase 2b trial [4] FASN Inhibitor Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis
My dad said, You dont have a butt anymore, Loren, 39, a digital-tech CEO, told The Post with a laugh
This loss accelerates during perimenopause and menopause due to declining estrogen levels
Our compassionate team is here to help you shed stubborn fat, improve your health, and rediscover your confidence
The GLP-1RAs have also been associated with minimal or no proteinuria reduction in small studies including kidney transplant recipients
